Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medically Underserved Area | 1 | 2024 | 121 | 0.220 |
Why?
|
| Vincristine | 3 | 2017 | 1582 | 0.210 |
Why?
|
| Anemia, Sickle Cell | 2 | 1998 | 364 | 0.210 |
Why?
|
| Neutropenia | 2 | 1996 | 1006 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 819 | 0.190 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 23 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 277 | 0.170 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 2 | 2001 | 46 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 1101 | 0.160 |
Why?
|
| Orbit | 1 | 2020 | 209 | 0.160 |
Why?
|
| Telemedicine | 1 | 2024 | 556 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 84 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1996 | 770 | 0.140 |
Why?
|
| Methylprednisolone | 2 | 2001 | 200 | 0.130 |
Why?
|
| Anemia, Refractory | 1 | 1995 | 40 | 0.130 |
Why?
|
| Hemoglobinuria | 1 | 1995 | 4 | 0.130 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2017 | 127 | 0.130 |
Why?
|
| Aminophylline | 1 | 1995 | 11 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 453 | 0.120 |
Why?
|
| Leukemia, Basophilic, Acute | 1 | 1995 | 3 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 1995 | 90 | 0.120 |
Why?
|
| Ceftriaxone | 1 | 1995 | 75 | 0.120 |
Why?
|
| Glucocorticoids | 2 | 1995 | 610 | 0.120 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1995 | 98 | 0.120 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1994 | 74 | 0.120 |
Why?
|
| Central Nervous System Diseases | 1 | 1995 | 134 | 0.120 |
Why?
|
| Hypoprothrombinemias | 1 | 1993 | 2 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 525 | 0.120 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1993 | 10 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 1995 | 123 | 0.110 |
Why?
|
| Dexamethasone | 1 | 1998 | 1525 | 0.110 |
Why?
|
| Infant | 9 | 2024 | 13994 | 0.110 |
Why?
|
| Lung Diseases | 1 | 1998 | 751 | 0.110 |
Why?
|
| Child, Preschool | 10 | 2024 | 17072 | 0.100 |
Why?
|
| Child | 12 | 2024 | 30560 | 0.100 |
Why?
|
| Methotrexate | 1 | 1995 | 1025 | 0.090 |
Why?
|
| Hemorrhage | 1 | 1993 | 724 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 6446 | 0.080 |
Why?
|
| Genotype | 1 | 2017 | 4248 | 0.080 |
Why?
|
| Adolescent | 9 | 2024 | 32689 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 4968 | 0.080 |
Why?
|
| Neoplasms | 2 | 2024 | 15949 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 5056 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1994 | 930 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 2903 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 1996 | 727 | 0.060 |
Why?
|
| Genetic Services | 1 | 2024 | 10 | 0.060 |
Why?
|
| Syndrome | 2 | 1998 | 1409 | 0.060 |
Why?
|
| Genomics | 2 | 2024 | 2832 | 0.050 |
Why?
|
| Female | 14 | 2024 | 148885 | 0.050 |
Why?
|
| Germ Cells | 1 | 2024 | 329 | 0.050 |
Why?
|
| Humans | 19 | 2024 | 270713 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 5777 | 0.040 |
Why?
|
| Male | 10 | 2024 | 128479 | 0.040 |
Why?
|
| Family | 1 | 2024 | 782 | 0.040 |
Why?
|
| Hemoglobin C Disease | 1 | 1998 | 3 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1249 | 0.040 |
Why?
|
| beta-Thalassemia | 1 | 1998 | 36 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 657 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 435 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2360 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 48 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2024 | 854 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 491 | 0.040 |
Why?
|
| Agranulocytosis | 1 | 1996 | 83 | 0.030 |
Why?
|
| Pneumocystis Infections | 1 | 1995 | 4 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1996 | 34 | 0.030 |
Why?
|
| Pneumocystis | 1 | 1995 | 15 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1995 | 74 | 0.030 |
Why?
|
| Fever | 1 | 1998 | 517 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 1998 | 580 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 186 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 191 | 0.030 |
Why?
|
| Hemolysis | 1 | 1995 | 125 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 1995 | 46 | 0.030 |
Why?
|
| Splenic Rupture | 1 | 1994 | 6 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2312 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1994 | 28 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1994 | 161 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 405 | 0.030 |
Why?
|
| Oxygen | 1 | 1998 | 786 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 2363 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 350 | 0.030 |
Why?
|
| Acute Disease | 1 | 1998 | 2492 | 0.030 |
Why?
|
| Age of Onset | 1 | 1995 | 853 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1995 | 476 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1996 | 350 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1995 | 818 | 0.030 |
Why?
|
| Adenosine | 1 | 1995 | 293 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1998 | 2574 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 301 | 0.030 |
Why?
|
| Prednisone | 1 | 1995 | 1034 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 10726 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 1995 | 465 | 0.020 |
Why?
|
| Length of Stay | 1 | 1998 | 1997 | 0.020 |
Why?
|
| Health Care Costs | 1 | 1996 | 696 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1996 | 1824 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 2986 | 0.020 |
Why?
|
| Prospective Studies | 2 | 1996 | 13419 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 9053 | 0.020 |
Why?
|
| Mycoses | 1 | 1994 | 393 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 7648 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1998 | 1467 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 4394 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1994 | 3145 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 4838 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 3245 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1994 | 4007 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 82041 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 5332 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8603 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 15917 | 0.010 |
Why?
|
| Quality of Life | 1 | 1996 | 4810 | 0.010 |
Why?
|
| Coombs Test | 1 | 2001 | 14 | 0.010 |
Why?
|
| Immune Sera | 1 | 2001 | 137 | 0.010 |
Why?
|
| Urine | 1 | 2001 | 134 | 0.010 |
Why?
|
| Nasopharynx | 1 | 2001 | 118 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 2001 | 179 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 494 | 0.010 |
Why?
|
| Prognosis | 1 | 1996 | 22528 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1998 | 33847 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 1101 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 1218 | 0.010 |
Why?
|
| Colloids | 1 | 1994 | 35 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1994 | 328 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 16741 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 718 | 0.010 |
Why?
|
| Biopsy | 1 | 1996 | 3490 | 0.000 |
Why?
|
| Recurrence | 1 | 1996 | 4878 | 0.000 |
Why?
|
| Time Factors | 1 | 1996 | 12978 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 7787 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1996 | 7916 | 0.000 |
Why?
|